PRDM9 and Miyoshi myopathy: In line with these data and those from chromatin-based epigenetic mechanisms, dual targeting of DNA methyltransferases (DNMTs) and the histone methyltransferase G9a promoted the osteogenic differentiation of MM-MSCs in vitro and prevented bone loss in an in vivo model of MM.